Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma.

Abstract

Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II). The patients had not received prior chemotherapy and were not eligible for radiotherapy and surgery. The overall response rate was 25% (5 of 20 patients). One patient with adenocarcinoma achieved a complete response, four achieved a partial response and three a minor response. In four patients the disease was stable. The response did not vary strictly with initial performance status as patients with a Karnofsky score of less than 70% also showed a median survival of 7.5+ months. The FAM II combination was very well tolerated, particularly regarding nausea and vomiting; the latter occurred in only one patient. No patient required a reduction in the drug dose because of leukopenia or thrombocytopenia.

• Authors: F Salvati, A R Cruciani, A De Marinis, F Nunziati, L Portalone
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 14 Issue 1 Pg. 3-6 (Mar 1984) ISSN: 0368-2811 [Print] England
• PMID: 6323790 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Mitomycins
• Tegafur
• Mitomycin
• Doxorubicin

Topics

• Adenocarcinoma (drug therapy, mortality)
• Adult
• Aged
• Alopecia (chemically induced)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Carcinoma, Bronchogenic (drug therapy, mortality)
• Carcinoma, Small Cell (drug therapy, mortality)
• Doxorubicin (administration & dosage, adverse effects)
• Female
• Humans
• Leukopenia (chemically induced)
• Lung Neoplasms (drug therapy, mortality)
• Male
• Middle Aged
• Mitomycin
• Mitomycins (administration & dosage, adverse effects)
• Nausea (chemically induced)
• Tegafur (administration & dosage, adverse effects)
• Thrombocytopenia (chemically induced)